Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials

Subodh Verma1,5,8,11*, Shaun G. Goodman2,6,9, Shamir R. Mehta12,13, David A. Latter1,5,8, Marc Ruel14, Milan Gupta9,12,15, Bobby Yanagawa1,5,8, Mohammed Al-Omran3,5,8,11, Nandini Gupta16, Hwee Teoh1,4,5,6 and Jan O. Friedrich6,7,9,10*

Abstract

Background: We assessed the effectiveness of dual antiplatelet therapy (DAPT) post elective or urgent (i.e., post acute coronary syndrome [ACS]) coronary artery bypass graft surgery (CABG).

Methods: We systematically searched MEDLINE, EMBASE, and the Cochrane Registry from inception to August 2015. Randomized controlled trials (RCTs) in adults undergoing CABG comparing either dual vs. single antiplatelet therapy or higher- vs. lower-intensity DAPT were identified.

Results: Nine RCTs (n = 4,887) with up to 1y follow-up were included. Five RCTs enrolled patients post-elective CABG (n = 986). Two multi-centre RCTs enrolled ACS patients who subsequently underwent CABG (n = 2,155). These 7 RCTs compared clopidogrel plus aspirin to aspirin alone. Two other multi-centre RCTs reported on ACS patients who subsequently underwent CABG comparing higher intensity DAPT with either ticagrelor (n = 1,261) or prasugrel (n = 485) plus aspirin to clopidogrel plus aspirin. Post-operative anti-platelet therapy was started when chest tube bleeding was no longer significant, typically within 24–48 h. There were no differences in all-cause mortality in clopidogrel plus aspirin vs. aspirin RCTs; conversely, all-cause mortality was significantly lower in ticagrelor and prasugrel vs. clopidogrel RCTs (risk ratio[RR] 0.49, 95 % confidence interval[CI] 0.33–0.71, p = 0.0002; 2 RCTs, n = 1695; I² = 0 %; interaction p < 0.01 compared to clopidogrel plus aspirin vs aspirin RCTs). There were no differences in myocardial infarctions, strokes, or composite outcomes. Overall, major bleeding was not significantly increased (RR 1.31, 95 % CI 0.81–2.10, p = 0.27; 7 RCTs, n = 4500). There was heterogeneity (I² = 42 %) due almost entirely to higher bleeding reported for the prasugrel RCT which included mainly CABG-related major bleeding (RR 3.15, 95 % CI 1.45–6.87, p = 0.004; 1 RCT, n = 437).

(Continued on next page)
Conclusions: Most RCT data for DAPT post CABG is derived from subgroups of ACS patients in DAPT RCTs requiring CABG who resume DAPT post-operatively. Limited RCT data with heterogeneous trial designs suggest that higher intensity (prasugrel or ticagrelor) but not lower intensity (clopidogrel) DAPT is associated with an approximate 50% lower mortality in ACS patients who underwent CABG based on post-randomization subsets from single RCTs. Large prospective RCTs evaluating the use of DAPT post-CABG are warranted to provide more definitive guidance for clinicians.

Keywords: Coronary artery bypass graft surgery, Acute coronary syndrome, Anti-platelet therapy, P2Y\textsubscript{12} antagonists, Systematic review, Meta-analysis

Background
Dual antiplatelet therapy (DAPT) with acetylsalicylic acid (ASA) and an oral P2Y\textsubscript{12} antagonist, is the cornerstone for management of patients presenting with acute coronary syndrome (ACS). Although there are no recommendations regarding DAPT treatment post elective CABG, guidelines recommend that therapy with DAPT be continued for one year following ACS (non-ST segment elevation myocardial infarction [NSTEMI], ST-elevation myocardial infarction [STEMI] or unstable angina), irrespective of whether patients are managed medically or invasively with either percutaneous coronary intervention or coronary artery bypass graft (CABG) surgery [1, 2]. The evidence supporting the benefit of DAPT in ACS patients has been based largely on three landmark trials, namely CURE [3], TRITON-TIMI 38 [4] and PLATO [5]. Whereas cardiac surgeons are well versed with the guidelines regarding discontinuation of DAPT prior to CABG to minimize bleeding risks [6, 7], there is considerable variability in DAPT resumption in ACS patients post CABG [8–10]. Since only a small proportion of patients in large trials undergo CABG, individual RCTs have not been adequately powered to address the role of DAPT in the post-CABG cohort. We therefore, conducted a meta-analysis of RCTs to evaluate the benefits of DAPT resumption in post CABG patients, either elective or post ACS, using all-cause mortality as the pre-specified primary endpoint.

Study Selection
We included prospective clinical trials randomizing adult patients with coronary artery disease undergoing CABG either 1) to dual vs single antiplatelet therapy (e.g., clopidogrel plus ASA vs ASA alone) or 2) to higher vs lower intensity dual antiplatelet therapy (e.g., ticagrelor or prasugrel plus ASA vs clopidogrel plus ASA). To meet inclusion criteria, RCTs had to either include only patients undergoing CABG, or report outcomes separately in subgroups of patients with ACS who underwent CABG. Studies were excluded if patients were not randomized between treatment groups or if outcomes were not reported separately for patients undergoing CABG.

Data Extraction and Quality Assessment
Details of the publication (i.e., trial authors and acronym, enrolment period, year of publication), inclusion/exclusion criteria, demographics and cardiac risk factors of the enrolled patients, description of the interventions used, and outcome definitions and events were collected and collated. Risk of bias in RCTs (including blinding of participants, method of sequence generation and allocation concealment, intention-to-treat analysis, early trial stopping for efficacy before the planned enrollment was completed, and loss to follow-up) was also assessed.

Methods
Data sources
We systematically searched OVID versions of MEDLINE (1946 through to August 2015, week 2), EMBASE Classic and EMBASE (1947 through 2015 week 34), and the Cochrane Central Register of Controlled Trials (July 2015) for relevant studies using search terms for anti-platelet agents and coronary artery bypass surgery, and published sensitive filters to identify randomized controlled trials (RCTs) (Fig. 1). We also searched bibliographies of included studies and personal files. We did not impose language restrictions.
reported, otherwise all major bleeding). The primary analysis included all patients in an intention to treat analysis. Prespecified subgroup analyses were conducted comparing 1) dual vs single antiplatelet therapy trials in elective CABG patients, to 2) dual vs single antiplatelet therapy trials in ACS patients who underwent CABG, to 3) higher intensity vs lower intensity dual antiplatelet trials in ACS patients who underwent CABG. We planned to also conduct a supplementary “on treatment” analysis including only patients who were actually continued on study drugs post-operatively, but these data were only available for one outcome (mortality) for one trial [11]. All meta-analyses were performed using Review Manager (RevMan version 5.2; Cochrane Collaboration, Oxford, UK) by one of the

| MEDLINE <1946 to August Week 2 2015> and EMBASE Classic+EMBASE <1947 to 2015 Week 34> |
|-----------------------------------|-----------------------------------------------------|
| 1 (clopidogrel or ticagrelor or prasugrel).mp. (53,624) |  |
| 2 (coronary artery bypass or cardiac surgery or heart surgery or CABG).mp. (259,397) |  |
| 3 1 and 2 (5,117) |  |
| 4 random:.tw. or clinical trial:.mp. (3,145,438) [EMBASE sensitive filter for randomized trials] |  |
| 5 clinical trial.mp. or clinical trial.pt. or random:.mp. or tu.xs. (6,193,652) [MEDLINE sensitive filter for randomized trials] |  |
| 6 3 and (4 or 5) (2,414) |  |
| 7 remove duplicates from 6 (2,148) |  |

Cochrane Central Register of Controlled Trials: Issue 7 of 12 July 2015
1 clopidogrel coronary bypass (222) [citations containing all three terms anywhere in title, abstract, or keywords]

2330 citations excluded based on screening criteria

40 references retrieved for detailed evaluation

31 references excluded
12 - Elective CABG RCTs
6 - single-centre short term trials with no outcome events: clopidogrel+ASA vs ASA [25-28], (including one duplicate publication [31]) or clopidogrel+ASA vs clopidogrel [24]  
4 - single anti-platelet comparisons, clopidogrel vs ticlopidine [32] or clopidogrel vs ASA [33-35]  
2 - published only as conference abstract with no reported outcome events: ticagrelor+ASA vs ASA [29] or clopidogrel+ASA vs ASA [30]

10 - ACS, CABG Subgroup RCTs
5 - No separate CABG subgroup data reported [38-42]  
2 - Intervention only pre-CABG [43*, 44]

4 - ACS, CABG Subgroup [11, 17-19]

9 RCTs included in meta-analysis

8 - Non-RCTs/Other [10, 72-78]

*Short term intervention pre-PCI (mean 4 days) and minimal resumption of study drug post CABG (8/136 [6%]) in CLARITY-TIMI 28 [43]

Fig. 1 Search strategy and trial flow. Flow chart for the systematic review and meta-analysis showing the search strategy, and the number of studies retained and number of studies excluded with reason for exclusion at each stage of the study selection process [72–78]
authors (JOF). Random effects models [12] which incorporate between-trial heterogeneity and give wider and more conservative confidence intervals (CI) when heterogeneity is present were used for all analyses. Statistical heterogeneity among trials was assessed using $I^2$, defined as the percentage of total variability across studies attributable to heterogeneity rather than chance, and using published guidelines for low ($I^2 = 25\%–49\%$), moderate ($I^2 = 50\%–74\%$) and high ($I^2 \geq 75\%$) heterogeneity [13]. Risk ratios (RR) were used to pool outcomes with a two-sided significance level of 5%. Individual trial and summary results are reported with 95% CIs. Differences between pooled RRs were evaluated using z tests. To assess for publication bias, a funnel plot comparing effect measure for the primary outcome of mortality to study precision was examined for evidence of asymmetry. Further more formal statistical testing for funnel plot asymmetry was not carried out due to the low number of RCTs meeting inclusion criteria (<10) which would result in low statistical power to distinguish chance from real asymmetry [14].

We contacted authors of included trials to clarify outcome data when required. Authors of one trial provided the numbers of patients who sustained myocardial infarctions and informed us that rates of stroke were not measured [15]. For the remainder we were informed that no additional data were available [11, 16–18]. For two ACS trials only the composite outcome of either cardiovascular [19] or all-cause mortality [18], MI, and stroke were reported for the subgroup of patients who underwent CABG. Authors of one of these trials provided individual event rates [19]. For the other trial, we estimated all-cause mortality, MI, and stroke rates assuming the same overall ratios of the separate outcomes to the composite outcome for each randomized group as reported in the main trial publication [20].

**Results**

The initial search strategy yielded 2148 citations from MEDLINE and EMBASE, and 222 citations from Cochrane, of which 40 were retrieved for full text review. Nine RCTs met inclusion criteria (Fig. 1) [11, 15–19, 21–23]. Details regarding excluded RCTs are provided in Additional file 1: Table S1. In brief, RCTs in patients post elective CABG were excluded if no outcome events occurred or were reported [24–30] (including duplicate publication [31]) or single anti-platelet therapies were used in both randomized groups [32–35] (including duplicate publications [36, 37]). RCTs enrolling patients with ACS were excluded if no separate outcome data was available for the subgroup of patients who underwent CABG (CHARISMA [38], DISPERSE-2 [39], COMMIT [40], TRILOGY ACS [41], and JUMBO-TIMI 26 [42]), patients were not treated with dual anti-platelet therapy post CABG (CLARITY-TIMI 28 [43] and CURRENT OASIS 7 [44]), trials reported only on patients previously treated with CABG but not during the study period (CAPRIE [45] and PLATO [46]); or patients were randomized to a non-P2Y$_12$ antagonist (TRACER [47]). One RCT in elective CABG patients was ongoing [48].

### Description of Included Studies and Quality Assessment

Table 1 provides details of the trials including baseline patient characteristics. Of the 9 included RCTs, five were single- [15, 16, 22, 23] or two-centre [21] RCTs that enrolled patients post elective CABG and compared clopidogrel plus ASA to ASA alone. One trial specified that ASA was not held pre-operatively [21]. ASA and clopidogrel were restarted post-operatively when chest tube bleeding was no longer significant, typically within 24–48 h. Patients were randomized either pre- [16] or post-[15, 21, 22] operatively. In one trial [23], patients were randomized on postoperative day 4 while on aspirin to clopidogrel add on but only if found to be aspirin resistant on aggregometry-based assessment.

The other four RCTs were all large multicentre trials enrolling patients with ACS that reported data separately for the subgroup of patients who underwent CABG [11, 17–19]. Of the ACS trials, 2 compared clopidogrel plus ASA to ASA alone [3, 20], and 2 compared higher intensity dual anti-platelet therapy with either ticagrelor [5] or prasugrel [4] plus ASA vs clopidogrel plus ASA. CREDO [20] enrolled patients who were referred for coronary angiography with symptomatic coronary artery disease (angina pectoris, positive stress test, or dynamic electrographic changes). CURE [3] enrolled patients with acute ischemic symptoms and either electrographic changes and/or elevation of cardiac enzymes to indicate myocardial necrosis, but excluded patients with ST elevation. Both PLATO [5] and TRITON-TIMI 38 [4] had similar inclusion criteria and allowed patients with either ST depression or ST elevation ACS. In TRITON-TIMI 38 [4] the coronary anatomy had to be defined and suitable for percutaneous coronary intervention (PCI) before randomization, hence a smaller percentage of patients progressed to CABG in this trial. In three of the included ACS trials [3–5], ASA and blinded second anti-platelet therapies were started shortly after presentation, whereas for CREDO [20] both randomized groups received dual anti-platelet therapy with clopidogrel for the first 28 days and then the control group received placebo for the remainder of the 1 year treatment period. For patients subsequently requiring CABG, the second anti-platelet therapy or corresponding placebo was typically held between 1 and 7 days pre-operatively, and then re-started post-operatively in the majority (62–76%) of patients (Table 1) [11, 17, 19]. For CURE [19] and CREDO [18] outcome data was provided for all patients who underwent CABG. For PLATO outcome data were provided
## Table 1 Trial and Baseline Patient Characteristics, and Interventions

| Patients Randomised Post Elective CABG | Patients Randomized with ACS or symptomatic CAD - CABG Subgroup |
|---------------------------------------|---------------------------------------------------------------|
| Clopidogrel 300 then 75 mg/d vs placebo | Clopidogrel 300 then 75 mg/d vs placebo |
| Clopidogrel 75 mg/d vs placebo | Ticagrelor 180 then 90 mg bid vs Clopidogrel 300 then 75 mg/d |
| Prasugrel 60 then 10 mg/d vs Clopidogrel 300 then 75 mg/d |

### ASA Dose (mg/d)
- Clopidogrel 300 then 75 mg/d vs placebo: 325 vs 75-325
- Ticagrelor 180 then 90 mg bid vs Clopidogrel 300 then 75 mg/d: 75-100 vs 75-162
- Prasugrel 60 then 10 mg/d vs Clopidogrel 300 then 75 mg/d: 75-100 vs 75-162

### Trial
- Sun et al. [16]
- Gao et al. [15]
- CASCADE [21]
- CRYSSA [22]
- Gasparovic [23]
- CREDO [18]
- CURE [19]
- PLATO [17]
- TRITON-TIMI 38 [11]

### n = CABG/total patients
- n = 100/100
- n = 249/249
- n = 300/300
- n = 224/224
- n = 83/2116
- n = 2072/12562
- n = 113/113
- n = 300/300
- n = 224/224
- n = 1261 (1899)/18624
- n = 346 (485)/13608

### Trial Characteristics

| No. of Centres | Enrolment period | Treatment/ Follow Up Post Randomization | Median Time to CABG Post Randomization | Treatment/ Follow Up Post CABG | Funding | Patients | Mean Age (years) | % Male | BMI | Diabetes | Hypertension | Smoker | COPD | Dyslipidemia |
|----------------|------------------|----------------------------------------|---------------------------------------|-------------------------------|---------|-----------|-----------------|--------|-----|----------|-------------|--------|------|-------------|
| 1              | Nov 2006 – Feb 2008 | 30 (all)/49 (median) d | n/r (index CABG instead of PCI) | 30 (all)/49 (median) d | Public/ Industry | n = 99 | 65 | 90 | 31 | 35 | 70 | 59.6 | 76 |
| 1              | Dec 2007 – Dec 2008 | 3 months (all) | 25.5 days (IQR 12–70.5) | 3 months (all) | Public/ Industry | n = 113 | 59 | 83 | 26 | 40 | 59 | 55.8 | 38 |
| 2              | May 2006 – Jul 2008 | 12 months (all) | ~12 months (all) | 12 months (all) | Public/ Industry | n = 300 | 67 | 89 | 28 | 29 | 50 | 13.2 | 88 |
| 1              | Dec 2006 – Oct 2009 | 12 months (all) | ~8 months (mean) | 12 months (all) | n/r | n = 219 | 59 | 74 | 26 | 29 | 46 | 36 | 56 |
| 1              | Jun 2010 – Feb 2013 | 6 months (all) | ~12 months (all) | 6 months (all) | n/r | n = 224 | 65 | 75 | 29 | 29 | 96 | 33 | 96 |
| 1              | Jun 1999 – Apr 2001 | 12 months (all) | ~8 months (mean) | 12 months (all) | n/r | n = 224 | 61 | 74 | 29 | 29 | 96 | 33 | 96 |
| 1              | Dec 1998 – Sep 2000 | 9 months (mean) | ~12 months (mean) | 9 months (mean) | n/r | n = 2072 | 64 | 70 | 29 | 29 | 61 | 33 | 96 |
| 1              | Oct 2006 – Jul 2008 | 224 days (7.5 months) (median) | ~200 days (6.7 months) (median) | 224 days (7.5 months) (median) | n/r | n = 1261 | 64 | 79 | 27 | 27 | 61 | 64.5 | 54 |
| 1              | Nov 2004 – Jan 2007 | 14.5 months (median) | ~11.2 months (median) | 14.5 months (median) | n/r | n = 346 | 31 | 77 | 27 | 27 | 64 | 31.2 | 54 |

Verma et al. BMC Surgery (2015) 15:112
| Characteristic                        | 39 %   | 47 %   | n/r     | 36 %   | 37 %   | 36 %   | 20 %   | n/r (18 %)<sup>b</sup> |
|--------------------------------------|--------|--------|---------|--------|--------|--------|--------|------------------------|
| Prev MI                               |        |        |         |        |        |        |        |                        |
| Prev stroke/TIA                       | 5.1 %  | 4.9 %  | n/r     | n/r    | n/r    | n/r    | 3.9 %  | 3.9 %/3.1 %            |
| Periph Vasc Dz                        | 5.1 %  | n/r    | n/r     | n/r    | 6.2 %  | 9.7 %  | 7.6 %  | 7.0 %                  |
| Chronic Renal Disease excl Cr >130 μM| n/r    | n/r    | n/r     | n/r    | n/r    | n/r    | 4.8 %  | n/r (11 % CrCl < 60 mL/min)<sup>b</sup> |
| Mean LVEF                             |        |        |         |        |        |        |        |                        |
| CHF                                  |        |        |         |        |        |        |        |                        |
| Severe LV dysfunction                 | 38 % (Gr 3 LV) | 0 % (excl) | n/r     | n/r    | n/r    | Excluded | 3.9 % (EF ≤ 30 %) |
| Previous PCI                          |        |        |         |        |        |        |        |                        |
| Recent CABG                           |        |        |         |        |        |        |        |                        |
| ST depression                         |        |        |         |        |        |        |        |                        |
| ST elevation                          |        |        |         |        |        |        |        |                        |
| Abnormal ECG                          |        |        |         |        |        |        |        |                        |
| Diagnosis: UA                         |        |        |         |        |        |        |        |                        |
| Diagnosis: MI                         |        |        |         |        |        |        |        |                        |
| Abnormal ECG/enzymes                  |        |        |         |        |        |        |        |                        |
| CABG                                  |        |        |         |        |        |        |        |                        |
| % Off-pump CABG                       | 0 %    | 58.0 % | 3.6 %   | 100 %  | 0 %    |        |        |                        |
| % arterial conduits                   | 100 %  | 100 %  | 100 %   | 100 %  | 93 %   |        |        |                        |
| Grafts or diseased vessels           | 4.0    | 3.1    | 3.5 ± 0.7| 3.2 ± 0.6| n/r    | 1–2 (31 %) | a1 (14.4 %) | 3–4 (60 %) | a2 (61.5 %) | ≥5 (8 %) | a3 (20.5 %) |
| Median (IQR) days to CABG (all)       | 25.5 (12–70.5) | ~20 | 100 (36) | |
| CABG pre-d/c                          |        |        |         |        |        |        |        |                        |
| Median (IQR) days to CABG pre-d/c     | 49 %   | 57 %   | 4.3 %   |        |        |        |        |                        |
| CABG post-d/c                         |        |        |         |        |        |        |        |                        |
Table 1 Trial and Baseline Patient Characteristics, and Interventions (Continued)

| Characteristic                        | Median (IQR) days to CABG post d/c | ≤2d (30.1 %) 3-5d (43.8 %) >5 (26.1 %) | ≤2d (25.1 %) 3-5d (29.0 %) >5 (45.4 %) |
|---------------------------------------|------------------------------------|----------------------------------------|----------------------------------------|
| Days off study drug before CABG       | 17 (9–33)                          | 66.4 %                                 | 61.8 % (214/346); additional 21/173 prasugrel and 16/173 clopidogrel patients resumed open label clopidogrel |
| Restarted treatment post CABG         | 76.1 % (66 never discontinued + 1451 resumed/1928; 78 data unavailable) | n/r                                    | n/r                                    |
| Days off study drug after CABG        | 10 (6–25)                          | <7d (35.9 %)                           | n/r                                    |
|                                       |                                    | 7–14 (16.8 %)                          |                                        |
|                                       |                                    | >14d (10.0 %)                          |                                        |

In CREDO, both groups receive clopidogrel 75 mg/day for 28 days before control group changed to placebo from day 29 through 12 months.

Proportion of all 13,608 randomized patients when data not provided for CABG subgroup in TRITON-TIMI 38.

Abbreviations: ACS acute coronary syndrome, ASA acetylsalicylic acid (aspirin), BMI body mass index, CABG coronary artery bypass grafting, CAD coronary artery disease, CHF congestive heart failure, COPD chronic obstructive pulmonary disease, d/c (hospital) discharge, DM diabetes mellitus, Dx diagnosis, Dz disease, ECG electrocardiogram, EF ejection fraction, excl excluded, incl included, IQR inter-quartile range, LM left main artery disease, LV left ventricle, mg milligram, MI myocardial infarction, mM millimolar, n number of patients, no. number, n/r not reported, PCI percutaneous coronary intervention, periph peripheral, prev previous, pts patients, Rx treatment, sd standard deviation, TIA transient ischemic attack, vasc vascular, 3VD triple vessel disease, UA unstable angina, vasc vascular.
only for the 1261 of 1899 patients that underwent CABG who received study drug within 7 days prior to the procedure [17]. For TRITON-TIMI 38 all outcome data were only provided for the 346 of 485 randomized patients that underwent CABG who received at least one dose of study drug prior to the procedure [11]; additional outcome data on all randomized patients that underwent CABG were provided in a FDA presentation [49].

For all trials, enrolled patients had a mean age around 60 years old, were predominantly male, and had the expected prevalence of various coronary risk factors (Table 1). 18–47 % of patients had previous myocardial infarction, and a small percentage (3–8 %) had previous stroke. A small percentage had also previously been treated with PCI or CABG. Patients with heart failure or severe left ventricular dysfunction were generally excluded. Some trials used off-pump surgery, and all patients received multiple grafts with at least one arterial conduit.

As shown in Table 1, in the 5 RCTs enrolling elective CABG patients, all patients were enrolled at the time of CABG and followed up for 12 months in two trials [21, 22], 6 months in one trial [23], 3 months in one trial [15], and a minimum of 30 days (median 49 days) in the fifth trial [16]. In 3 of the 4 RCTs enrolling ACS patients, CABG occurred at a median time of 20–100 days post-randomization [17, 19, 50] and patients were followed for a median of 6.7 to 11.2 months post CABG. Time to CABG and follow up duration was similar between groups in each trial. The fourth ACS trial enrolling patients expected to require PCI did not specifically report time to CABG but included only patients who were treated with CABG instead of PCI at study enrolment implying treatment shortly after randomization, and followed all patients for 12 months post randomization [18]. For all trials only clinical outcomes that occurred post CABG were included.

Study quality was relatively high (Table 2). Allocation was concealed in all trials except for one single-centre trial where it was unclear [15], and all studies except for three single-centre trials [15, 22, 23] blinded participants using placebos. All trials used intention-to-treat analysis, were not stopped early for benefit, and had ≤5 % (and for the large multi-centre trials ≤0.1 %) of randomized patients with missing outcome data.

Quantitative Data Synthesis

All-Cause Mortality (Fig. 2): Pooling data from all RCTs, there was no difference in all-cause mortality (RR 0.68, 95 % CI 0.43–1.08, p = 0.10) with some heterogeneity ($I^2 = 39$ %). The clopidogrel plus ASA vs ASA RCTs showed no difference in all-cause mortality for either the elective CABG (RR 0.56, 95 % CI 0.18–1.67, p = 0.29) or the ACS CABG subgroups (RR 1.18, 95 % CI 0.83–1.66, p = 0.36). However, the ticagrelor or prasugrel vs clopidogrel RCTs showed significantly lower risk for all-cause mortality (RR 0.49, 95 % CI 0.33–0.71, p = 0.0002). There was no heterogeneity within any of the subgroups ($I^2 = 0$ %). The differences between the clopidogrel plus ASA vs ASA elective CABG and ACS subgroups (either individually or combined), and the ticagrelor or prasugrel vs clopidogrel subgroup results were statistically significant (interaction p-value 0.002–0.007). Visual inspection of the funnel plot showed no evidence of asymmetry (data not shown).

Other Clinical Outcomes: Neither dual vs single nor higher-intensity vs lower-intensity dual anti-platelet therapy resulted in decreased myocardial infarction (RR 0.91, 95 % CI 0.69–1.20, p = 0.52; Fig. 3a) or stroke (RR 1.10, 95 % CI 0.75–1.62, p = 0.61; Fig. 3b) with similar non-significant treatment effects in the dual vs single anti-platelet and higher-intensity vs lower-intensity DAPT subgroups ($I^2 = 0$ %). Likewise the composite outcome of death from cardiovascular causes (all-cause mortality for CRYSSA [22] and CREDO [18]), myocardial infarction, and stroke (only cardiovascular death and myocardial infarction for Gao 2010 [15]) remained non-significant (Fig. 3c): RR 0.86, 95 % CI 0.73–1.03, p = 0.10, with no differences in results between subgroups ($I^2 = 0$ %).

### Table 2 Quality assessment of included randomized controlled trials

| Trial               | Blinded | Concealed allocation | Intention to treat analysis | Not stopped early for benefit | < 5 % Randomized Patients with Missing Outcome Data |
|---------------------|---------|----------------------|-----------------------------|-------------------------------|-----------------------------------------------|
| CURE [3, 19]        | Yes     | Yes (central randomization) | Yes                         | Yes                           | Yes (0.1 %: 13/12,562 overall; 0 % of CABG) |
| PLATO [5, 17]       | Yes     | Yes (central randomization) | Yes                         | Yes                           | Yes (0.03 %: 5/18,624 overall)                |
| TRITON-TIMI 38 [H, 11] | Yes     | Yes (central randomization) | Yes                         | Yes                           | Yes (0.1 %: 14/13,608 overall)                |
| CREDO [18, 20]      | Yes     | Yes                  | Yes                         | Yes                           | Yes (0 %)                                    |
| CRYSSA [22]         | No      | Yes                  | Yes                         | Yes                           | Yes (0.3 %: 1/300)                            |
| CASCADE [21]        | Yes     | Yes                  | Yes                         | Yes                           | Yes (0 %)                                    |
| Gao 2010 [15]       | No      | Unclear              | Yes                         | Yes                           | Yes (3.7 %: 9/249)                            |
| Sun 2010 [16]       | Yes     | Yes                  | Yes                         | Yes                           | Yes (1.0 %: 1/100)                            |
| Gasparovic 2014 [23]| No      | Yes                  | Yes                         | Yes                           | Yes (2.2 %: 5/224)                            |
Bleeding: The clopidogrel plus ASA vs ASA trials that reported bleeding used CURE trial [19, 21, 22], Bleeding Academic Research Consortium (BARC) Bleeding Definitions [51] Type 3–5 [23] or similar [16] criteria for major bleeding and reported events that were either non-CABG related [16, 21–23] or more than 7 days post CABG [19]. The higher-intensity vs lower-intensity DAPT trials reported bleeding using TIMI criteria and included both CABG-related and non-CABG-related bleeding. One of these trials specifically stated that “nearly all bleeding events occurred within 24 h post-CABG” [17]. Overall, major bleeding was not significantly increased (RR 1.31, 95 % CI 0.81–2.10, p = 0.27; Fig. 4) with some heterogeneity ($I^2 = 42 \%$) but no differences between subgroup results. The heterogeneity was due entirely to the significantly higher bleeding rate reported for TRITON-TIMI 38 ($I^2 = 0 \%$ when the results of this trial are excluded).

**Discussion**

The results from this analysis suggest that DAPT resumption with higher intensity P2Y12 antagonists (prasugrel or ticagrelor), but not clopidogrel reduces all-cause mortality in ACS patients who have undergone CABG. However, these results are based on post-randomization subsets from single RCTs where DAPT was initiated prior to CABG, with the intention of continuing therapy for one year post revascularization. Although it would have been invaluable to compare the outcomes in patients who continued DAPT vs. those in whom therapy was not resumed post-CABG, these data were not available. Likewise, there are no RCTs wherein ACS patients were randomized to receive DAPT vs. ASA following CABG. Finally, the number of patients enrolled in elective CABG RCTs was considerably smaller, and the pooled results of these RCTs comparing exclusively clopidogrel plus ASA to ASA alone post operatively demonstrated no differences in outcomes.
### Table A: DAPT or High Intens. DAPT vs. ASA or Low Intensity DAPT

| Study or Subgroup | DAPT or High Intens. DAPT | ASA or Low Intensity DAPT | Risk Ratio | Risk Ratio |
|-------------------|---------------------------|---------------------------|------------|------------|
| Events | Total | Events | Total | Weight | IV, Random, 99% CI | IV, Random, 99% CI |
| CABG/DR 2010 | 4 | 66 | 1 | 57 | 1.6% | 4.07 (0.47, 3.51) |
| GISSI 1998 | 1 | 124 | 0 | 125 | 0.7% | 3.52 (0.12, 10.52) |
| Sun 2010 | 0 | 49 | 0 | 50 | Hot estimate |
| CRITICAL 2012 | 7 | 140 | 6 | 150 | 4.0% | 0.50 (0.12, 1.98) |
| OCAPS 2014 | 1 | 112 | 1 | 113 | 1.0% | 0.96 (0.06, 15.08) |
| Subtotal (95% CI) | 66 | 489 | 46 | 545 | 5.4% | 1.05 (0.36, 2.53) |
| Total events | 9 | 0 | 0 | 0 | 0 |

Heterogeneity: Tau² = 0.02, CH² = 3.05, df = 3 (P = 0.39), N = 2
Test for overall effect: Z = 0.99 (P = 0.32)

### Table B: DAPT or High Intens. DAPT vs. ASA or Low Intensity DAPT

| Study or Subgroup | DAPT or High Intens. DAPT | ASA or Low Intensity DAPT | Risk Ratio | Risk Ratio |
|-------------------|---------------------------|---------------------------|------------|------------|
| Events | Total | Events | Total | Weight | IV, Random, 99% CI | IV, Random, 99% CI |
| CABG/DR 2010 | 4 | 66 | 1 | 57 | 1.6% | 4.07 (0.47, 3.51) |
| GISSI 1998 | 1 | 124 | 0 | 125 | 0.7% | 3.52 (0.12, 10.52) |
| Sun 2010 | 0 | 49 | 0 | 50 | Hot estimate |
| CRITICAL 2012 | 7 | 140 | 6 | 150 | 4.0% | 0.50 (0.12, 1.98) |
| OCAPS 2014 | 1 | 112 | 1 | 113 | 1.0% | 0.96 (0.06, 15.08) |
| Subtotal (95% CI) | 66 | 489 | 46 | 545 | 5.4% | 1.05 (0.36, 2.53) |
| Total events | 9 | 0 | 0 | 0 | 0 |

Heterogeneity: Tau² = 0.02, CH² = 3.05, df = 3 (P = 0.39), N = 2
Test for overall effect: Z = 0.99 (P = 0.32)

### Table C: DAPT or High Intens. DAPT vs. ASA or Low Intensity DAPT

| Study or Subgroup | DAPT or High Intens. DAPT | ASA or Low Intensity DAPT | Risk Ratio | Risk Ratio |
|-------------------|---------------------------|---------------------------|------------|------------|
| Events | Total | Events | Total | Weight | IV, Random, 99% CI | IV, Random, 99% CI |
| CABG/DR 2010 | 4 | 66 | 1 | 57 | 1.6% | 4.07 (0.47, 3.51) |
| GISSI 1998 | 1 | 124 | 0 | 125 | 0.7% | 3.52 (0.12, 10.52) |
| Sun 2010 | 0 | 49 | 0 | 50 | Hot estimate |
| CRITICAL 2012 | 7 | 140 | 6 | 150 | 4.0% | 0.50 (0.12, 1.98) |
| OCAPS 2014 | 1 | 112 | 1 | 113 | 1.0% | 0.96 (0.06, 15.08) |
| Subtotal (95% CI) | 66 | 489 | 46 | 545 | 5.4% | 1.05 (0.36, 2.53) |
| Total events | 9 | 0 | 0 | 0 | 0 |

Heterogeneity: Tau² = 0.02, CH² = 3.05, df = 3 (P = 0.39), N = 2
Test for overall effect: Z = 0.99 (P = 0.32)

Fig. 3 (See legend on next page.)
Among the higher-intensity P2Y₁₂ antagonist RCTs, it is important to highlight that in TRITON-TIMI 38 prasugrel was only initiated after the coronary anatomy was defined and PCI was planned [11]. The trial was not intended to recruit patients destined for CABG, although in the minority of patients who did undergo CABG, the prasugrel group yielded a significant reduction in mortality. Prasugrel was associated with an increased risk of major bleeds which was primarily CABG related. A subsequent analysis by the trial authors indicated that prasugrel-treated patients received higher platelet but not red blood cell transfusions [50].

Ticagrelor is a novel P2Y₁₂ antagonist, with a reversible mechanism of action. It provides more effective and...
reliable inhibition of platelet activity compared to clopidogrel [52], and recent data suggest that it may also have a unique pleiotropic effect to augment adenosine bioavailability [53]. In the PLATO trial, randomization for 1-year to DAPT with ticagrelor vs. clopidogrel reduced all-cause mortality in the entire cohort by 20%; the magnitude of benefit was particularly striking in those who underwent CABG (of whom approximately 66% were restarted on study drug), where an approximate 50% reduction in mortality was observed [17]. Interestingly, CABG related major bleeding, defined by various criteria was not different between ticagrelor vs. clopidogrel arms, and neither were the rate of transfusion or mean chest tube drainage. However, non-CABG related major bleeds were slightly higher in the ticagrelor vs. clopidogrel treated patients in all patients [5]. (Non-CABG related major bleed data was unfortunately unavailable for the CABG subset [17]). Since non-CABG related bleeding is likely the safety outcome of interest outside of the immediate perioperative period, surgeons must weigh the bleeding risk relative to the major reduction in all-cause mortality in choosing whether or not to resume DAPT with ticagrelor [54]. Recent data suggest that the adjusted hazard ratio for bleeding with ticagrelor does not increase with age [55].

The present analysis does not provide insight regarding what types of ACS patients are more likely to benefit from DAPT post CABG. It may be hypothesized that patients with diffuse disease (diabetes and chronic kidney disease for example), may be more likely to derive ongoing ischemic benefit by virtue of reduction in new atherothrombotic events. Likewise, analysis of benefit as a function of complexity of lesions (SYNTAX score for example) has not been conducted. Individualizing therapy based on residual platelet reactivity while on treatment which can vary widely between patients may help to better identify patients who would benefit from higher intensity anti-platelet therapy. For example, the most recently published trial included in this meta-analysis [23] attempted to do this by randomizing only patients to DAPT who still had high residual platelet reactivity while on ASA. Further studies aimed at better refining the subgroups that are more likely to derive the greatest ischemic benefit, and yield the lowest bleeding signal need to be performed.

Our systematic review and meta-analysis is the first to include both RCTs enrolling patients undergoing elective CABG and subgroups of patients presenting with ACS who subsequently require CABG. Furthermore, we also included RCTs that employed both higher- and lower-intensity dual antiplatelet therapies. Because results from these different types of RCTs may differ, we separated them into subgroups of RCTs for each analysis to highlight potential differences. Previous systematic reviews have been more restrictive either including only studies enrolling elective CABG patients [56–58], comparing lower intensity dual antiplatelet therapy with clopidogrel plus ASA to ASA [59], comparing dual or single antiplatelet therapy with clopidogrel to ASA [60, 61], or comparing higher- to lower-intensity dual anti-platelet therapy [62, 63]. These systematic reviews are in addition to those evaluating the use of dual anti-platelet therapy at the time of CABG [64–71]. We included all RCTs in any of these systematic reviews that met inclusion criteria for the current review.

Study Limitations
Although we used rigorous systematic review and meta-analytic methods consistent with PRISMA guidelines including a reproducible and comprehensive literature search strategy, clearly defined inclusion criteria, duplicate citation review, data abstraction, and quality assessment of individual studies, and a pre-defined analysis plan, we pooled results from studies that employed different inclusion/exclusion criteria, interventions, and follow-up periods. In particular, we pooled results from trials comparing dual vs single antiplatelet therapies (clopidogrel plus ASA vs ASA) with trials using different higher intensity dual platelet therapies (using ticagrelor or prasugrel) vs lower intensity dual platelet therapies (using clopidogrel). We also pooled results from trials enrolling elective CABG patients with ACS patients who were randomized to dual anti-platelet therapy groups and then subsequently required CABG. Recognizing these differences, we presented pooled results separately for each of these subgroups within each analysis. The small size of elective CABG patient trials resulted in few events highlighting the paucity of currently available data (as well as upcoming data from ongoing registered trials listed in Additional file 1: Table S1) in this specific patient population, making it difficult to assess either the benefits, in terms of reducing adverse cardiac events, or the harms, in terms of increased bleeding. Follow up duration was variable ranging from 1.5 to 12 months for the elective CABG patients trials, and 6–12 months for the trials enrolling ACS patients who subsequently required CABG. The majority of the patient data was obtained from the large multicentre trials enrolling patients with ACS in which only a subgroup of patients underwent CABG [11, 17–19], at various time points, up to a median of 100 days post randomization in one trial [50]. Although separate subgroup data for the patients treated with CABG have been reported in the ACS RCTs, the decision to undergo CABG is a post randomization event occurring at variable times post randomization. This decision can thus be influenced by randomized group resulting in potential baseline imbalances between intervention and control groups within the subgroup, though the baseline characteristics reported for the subgroups undergoing CABG were balanced in
these trials [11, 17–19]. Furthermore, in some of these trials, complete outcome data are only reported for some of the patients who underwent CABG [11, 17] and these patients may be lower risk than CABG ACS patients treated outside of clinical trials. Except for bleeding events in CURE which were reported greater than 7 days post CABG, bleeding events in the other ACS trials though reported postoperatively also included events related to the operation. For example, bleeding events in TRITON-TIMI 38 and PLATO included all post-operative events and one of these reports stated that “nearly all bleeding events occurred within 24 h post-CABG” [17]. Finally, for the subgroups of patients with acute coronary syndrome who underwent CABG, we analyzed the patients on an intention to treat basis; only 62–76 % of the patients in the three largest trials [11, 17, 19] resumed dual antiplatelet therapy post operatively. Incomplete resumption of assigned treatment will reduce apparent treatment and adverse effects. Only TRITON-TIMI 38 provided on-treatment data and then only for mortality [11]. Conducting an on-treatment analysis, if these data were available for all trials, may provide better efficacy data; however, this would involve incorporating a further post-randomization event potentially leading to non-comparable groups with dissimilar baseline characteristics. For ACS patients the timing of DAPT treatment is likely more complex since when DAPT is discontinued preoperatively (to maximize the ACS benefit and to minimize bleeding) and when DAPT is resumed postoperatively (to maximize post-operative benefits) may both potentially affect outcomes.

Conclusions
Based on the available but limited RCT data, resumption of anti-platelet therapy post operatively with higher intensity DAPT (prasugrel or ticagrelor with ASA) but not lower intensity DAPT (clopidogrel and ASA) appears to reduce all-cause mortality by about 50 % in patients with ACS who undergo CABG. With the caveat that the data are primarily based on retrospective subgroup analysis from single RCTs of ACS patients who progress to CABG, the net clinical benefit (efficacy vs. bleeding) appears to favour the use of ticagrelor in these patients. No significant benefits or harms were detected for DAPT after elective CABG, however, few such patients have been studied in randomized trials. The limited RCT data suggest that large prospective RCTs evaluating the use of DAPT post-CABG are urgently needed to provide more definitive guidance for clinicians.

Additional file

Additional file 1: Description of Excluded RCTs. (DOC 63 kb)
References

1. Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey Jr DE, et al. ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction ( updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2012;60:45–81.

2. Tanguay JF, Bell AD, Ackman ML, Bauer RD, Cartier R, Chan WS, et al. Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antithrombotic therapy. Can J Cardiol. 2013;29:334–45.

3. Yusuf S, Zhao F, Mehta SR, Chrolavics U, Tognoni G, Fox KA, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.

4. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruyzillo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–15.

5. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57.

6. Fitchett D, Eikelboom J, Friesen S, Mazer D, Singh S, Bittria B, et al. Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society. Can J Cardiol. 2009;25:5889–9.

7. Fitchett D, Mazer DC, Eikelboom J, Verma S. Antiplatelet therapy and cardiac surgery: review of recent evidence and clinical implications. Can J Cardiol. 2013;29:1042–7.

8. Krimly A, Yan RT, Yan AT, De'Young JP, Galaro R, Steg G, et al. Use of clopidogrel post-coronary artery bypass surgery in Canadian patients with acute coronary syndromes. Can J Cardiol. 2011;27:71–5.

9. Ruo RV, Goodman SG, Yan RT, Spencer FA, Fox KA, De'Young JP, et al. Temporal trends and patterns of early clopidogrel use across the spectrum of acute coronary syndromes. Am Heart J. 2009;157:642–9.

10. Groeneveld PW, Hlatky MA. Commentary. Evid Based Med. 2001;6:114.

11. Smith PK, Goodhough LT, Levy JH, Poston SH, Short MA, Weerakkody GJ, et al. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. J Am Coll Cardiol. 2012;63:88–96.

12. DeSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1981;2:177–88.

13. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.

14. Sterne JAC, Egger M, Moher D. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. Chapter 10: Addressing reporting biases. In: Cochrane Library, 2011.

15. Gao G, Zheng Z, Pi Y, Lu B, Lu J, Hu S. Aspirin plus clopidogrel therapy for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary artery RY Bypass occlusion After off-pump procedures) randomised study. Heart. 2012;98:1710–5.

16. Gasparovic H, Petricic M, Kopjar T, Dujic Z, Svetina L, Bicicova B. Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting. Am J Cardiol. 2014;113:1660–7.

17. Gao C, Ren C, Li D, Li L. Clopidogrel and aspirin versus clopidogrel alone on graft patency after coronary artery bypass grafting. Ann Thorac Surg. 2009;88:859–62.

18. Kayacioglu I, Gunay R, Saksen H, Idiriz M, Sensoz Y, Ates M, et al. The role of clopidogrel and acetylsalicylic acid in the prevention of early-phase graft occlusion due to reactive thrombocytosis after coronary artery bypass operation. Heart Surg Forum. 2008;11:E152–75.

19. Mujovic E, Nurki M, Calak J, Tericic L, Kabli E, Bergland J. The effect of combined clopidogrel and aspirin therapy after off-pump coronary surgery: a pilot study. Innovations (Phil). 2009;4:265–8.

20. Nielsen AB, Bochen P, Steinbruchel DA. Hypercoagulability and platelet inhibition after OPCAB. Randomized intervention with clopidogrel. Scand Cardiovasc J. 2007;41:325–30.

21. Wang X-Z, Gong X-Z, Zhu T-T, Li C-J, Yang Z-J. Effect of aspirin plus clopidogrel therapy on aspirin resistance after off-pump coronary artery bypass surgery [Chinese]. Acta Acad Med Sinic. 2013:35:495–502.

22. Saw JW, Wong G, Mayo J, Bemstein V, Mancini GB, Ye J, et al. Ticagrelor and Aspirin for the Prevention of Cardiovascular Events After Coronary Artery Bypass Surgery: The TAP-CABG Study. J Am Coll Cardiol. 2015;65:A1638.

23. Tropthe OS, Patel SP, Deshmukh RH. A study of aspirin plus clopidogrel versus aspirin alone on saphenous vein graft patency after coronary artery bypass graft surgery: an angiographic follow-up after three months. Indian Heart J. 2014;66:522.

24. Wang X, Gong X, Zhu T, Zhang Q, Zhang Y, Wang X, et al. Clopidogrel improves aspirin response after off-pump coronary artery bypass surgery. J Biome Res. 2014;28:108–13.

25. David JL, Linet R. Antiplatelet activity of clopidogrel in coronary artery bypass graft surgery patients. Thromb Haemost. 1999;82:1417–21.

26. Lim E, Comelissen J, Routledge T, Kirtland S, Charmian SC, Bellin S, et al. Clopidogrel did not inhibit platelet function early after coronary bypass surgery: A prospective randomized trial. J Thorac Cardiovasc Surg. 2004;128:432–5.

27. Suvalski G, Smoczyck C, Banach M, Gryczko L, Szaacki P, Krawczyk K, Hendzel P. Aspirin versus clopidogrel after off-pump coronary artery bypass grafting: Prospective, randomized head-to-head trial. In: 15th Annual Meeting of the International Society for Minimally Invasive Cardiothoracic Surgery, vol. 7. Los Angeles, 2012: 138.

28. Tietk S, Ak I, Ibir S, Eksioglu-Demiralp E, Arsan S, Iqbal O, et al. Clopidogrel provides significantly greater inhibition of platelet activity than aspirin when combined with atorvastatin after coronary artery bypass grafting: a prospective randomized study. Clin Appl Thromb Hemost. 2010;16:169–98.

29. Comelissen J, Kirtland S, Lim E, Goddard M, Bellin S, Sheridan K, et al. Biological efficacy of low against medium dose aspirin regimen after coronary surgery: analysis of platelet function. Thromb Haemost. 2006;95:476–82.

30. Lim E, Comelissen J, Routledge T, Ali A, Kirtland S, Sharpe L, et al. Biological efficacy of low versus medium dose aspirin after coronary surgery: results from a randomized trial [NCT01262275]. BMC Med. 2006;4:12.

31. Bharti DI, Fox KA, Hackle WI, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–17.

32. Cannon CP, Husted S, Harrington RA, Storella CM, Emanuelsson H, Peters G, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral antiplatelet agent. N Engl J Med. 2007;357:1844–51.

33. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. Addition of aspirin to atorvastatin reduces cardiovascular events in patients with intermediate cardiovascular risk: a randomized controlled trial. JAMA. 2002;288:2411–20.
42. Wiviott SD, Antman EM, Winters KJ, Weraakkody G, Murphy SA, Behounek BD, et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine PY2112 antagonist, with clopidogrel in percutaneous coronary intervention: results of the JOINT Utilization of Medications to Block Platelets Optimally (JUMP-TO)-TIMI 26 trial. Circulation. 2005;111:3366–73.

43. McLeer DS, Sabatine MS, Guo W, McCabe CH, Cannon CP. Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolitics in CLARITY-TIMI 28. J Thromb Thrombolysis. 2007;24:85–91.

44. Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Elekboom JW, Fox KA, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363:930–2.

45. Bhatt DL, Chew DP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation. 2001;103:363–8.

46. Brilakis ES, Held C, Meier B, Cools F, Claeys MJ, Cornel JH, et al. Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATElet inhibition and patient outcomes (PLATO) trial. Am Heart J. 2013;166:74–80.

47. WheFan DJ, Tricoci P, Chen E, Huang Z, Leibowitz D, Vanvck P, et al. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). J Am Coll Cardiol. 2014;63:1048–57.

48. Rafiq S, Johansson PI, Zia AA, Vuran AC, Cui H, Aytac A. Postoperative clopidogrel in patients with ST-elevation myocardial infarction treated with fibrinolitics in TEG-CABG trial: assessing and monitoring the antithrombotic effect of clopidogrel and aspirin versus aspirin alone in hypercoagulable patients: study protocol for a randomized controlled trial. Trials. 2012;13:48.

49. Eli Lilly and Company, Sankyo D. Effient (Prasugrel) Acute Coronary Syndromes Managed by Percutaneous Coronary Intervention. 2009.

50. Goodnough LT, Smith PK, Levy JH, Poston RS, Short MA, Weerakkody GJ, et al. Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel. TRITON-TIMI 38 retrospective data analysis. J Thorac Cardiovasc Surg. 2013;145:1077–82. e1074.

51. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Benefit of prasugrel versus clopidogrel in patients scheduled for percutaneous coronary interventions. Thromb Haemost. 2012;108:318–27.

52. Biondi-Zoccai G, Lotrionte M, Agostoni P, Abbate A, Romagnoli E, Sangiorgi G, et al. Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis. Heart. 2006;92:531–2.

53. Steiner S, Mootri D, Chen L, Coyle D, Wells GA. Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions. Thromb Haemost. 2012;108:318–27.

54. Biancari F, Airaksinen KE, Lip GY. Benefits and risks of using clopidogrel before coronary artery bypass surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial. J Thromb Thrombolysis. 2013;36:176–7.

55. Ibrahim K, Tjomsland O, Halvorsen D, Wiseth R, Wahba A, Karevold A, et al. Effect of clopidogrel on midterm graft patency following off-pump coronary revascularization surgery. Heart Surg Forum. 2006;9:851–856.